{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T23:43:42Z","timestamp":1649115822619},"reference-count":26,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1157\/13094416","type":"journal-article","created":{"date-parts":[[2006,11,16]],"date-time":"2006-11-16T13:55:54Z","timestamp":1163685354000},"page":"601-604","source":"Crossref","is-referenced-by-count":2,"title":["Valoraci\u00f3n de la mutaci\u00f3n V617F del gen JAK2 en s\u00edndromes mieloproliferativos cr\u00f3nicos con cromosoma Filadelfia negativo"],"prefix":"10.1016","volume":"127","author":[{"given":"\u00c1ngel F.","family":"Remacha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiomar","family":"Puget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep F.","family":"Nomded\u00e9u","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camino","family":"Estivill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pilar Sard\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carme","family":"Canals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13094416_bib1","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1200\/JCO.2005.05.010","article-title":"Genetics of myeloid malignancies: pathogenetic and clinical implications","volume":"23","author":"Frohling","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1157\/13094416_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2003-11-3896","article-title":"After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies","volume":"105","author":"Wadleigh","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13094416_bib3","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13094416_bib4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1157\/13094416_bib5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1157\/13094416_bib6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1157\/13094416_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1157\/13094416_bib8","first-page":"871","article-title":"Gain of function, loss of control \u2013 a molecular basis for chronic myeloproliferative disorders","volume":"90","author":"Cazzola","year":"2005","journal-title":"Haematologica"},{"key":"10.1157\/13094416_bib9","first-page":"159","article-title":"Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders","volume":"91","author":"Cazzola","year":"2006","journal-title":"Haematologica"},{"key":"10.1157\/13094416_bib10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1157\/13094416_bib11","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2005-04-1515","article-title":"The Jak2 V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients","volume":"106","author":"Goerttler","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13094416_bib12","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders","volume":"106","author":"Scott","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13094416_bib13","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u00abatypical\u00bb myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1157\/13094416_bib14","series-title":"Tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"key":"10.1157\/13094416_bib15","series-title":"Dise\u00f1o de investigaciones en ciencias de la salud. Dise\u00f1o para el estudio de pruebas diagn\u00f3sticas y factores pron\u00f3sticos","author":"Bolumar","year":"1999"},{"key":"10.1157\/13094416_bib16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1157\/13094416_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/asheducation-2005.1.201","article-title":"Management of polycythemia vera and essential thrombocythemia","volume":"59","author":"Campbell","year":"2005","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1157\/13094416_bib18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05743.x","article-title":"Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1157\/13094416_bib19","first-page":"41893","article-title":"JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor","volume":"280","author":"Staerk","year":"2005","journal-title":"J BiolChem"},{"key":"10.1157\/13094416_bib20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1157\/13094416_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/asheducation-2005.1.195","article-title":"A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases","author":"Vainchenker","year":"2005","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1157\/13094416_bib22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2005.05535.x","article-title":"Guidelines for the diagnosis, investigation and management of polycythaemia\/erythrocytosis","volume":"130","author":"McMullin","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1157\/13094416_bib23","doi-asserted-by":"crossref","first-page":"470","DOI":"10.7326\/0003-4819-139-6-200309160-00009","article-title":"The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis","volume":"139","author":"Ruggeri","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1157\/13094416_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-2007-996117","article-title":"Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis","volume":"23","author":"De Stefano","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"10.1157\/13094416_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.1162","article-title":"Genetic heterogeneity of primary familial and congenital polycythemia","volume":"68","author":"Kralovics","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1157\/13094416_bib26","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775306726847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775306726847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:53:27Z","timestamp":1587257607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775306726847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":26,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0025775306726847"],"URL":"https:\/\/doi.org\/10.1157\/13094416","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}